As National Make-a-Will Month comes to an end, strengthen your legacy and build a future of hope & progress for our loved ones and the #myeloma community. With our partner, FreeWill, you can create a will that reflects your wishes easily at no cost. By including an optional gift to the MMRF, you can extend your impact on the work we do to: 🔬 Accelerate the development of novel therapies 💉 Drive optimal and more personalized treatment approaches 📄 Provide critical information and resources for the best possible outcomes Create your will today: https://ow.ly/qTYx50SY2a6
Multiple Myeloma Research Foundation - MMRF
Non-profit Organizations
Norwalk, Connecticut 14,635 followers
Accelerating a smarter, faster, cure for mutiple myeloma.
About us
We drive the development and delivery of next-generation therapies, leverage data to identify optimal and more personalized treatment approaches, and empower myeloma patients and the broader community with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the MMRF has committed over $500 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients.
- Website
-
http://themmrf.org
External link for Multiple Myeloma Research Foundation - MMRF
- Industry
- Non-profit Organizations
- Company size
- 51-200 employees
- Headquarters
- Norwalk, Connecticut
- Type
- Nonprofit
- Founded
- 1998
Locations
-
Primary
383 Main Avenue
5th Floor
Norwalk, Connecticut 06851, US
Employees at Multiple Myeloma Research Foundation - MMRF
-
Pam Lewis
Leader in Fundraising, Patient Advocacy and Programming. Catalyst and Pied Piper.
-
Christopher Williams
-
Adriana Davis
Producer/Editor/Voice-Over Artist, Director
-
Lori Tauber Marcus
Experienced Board Director, Chair, Compensation Committee, Nominating Governance Committee, Audit Committee, Board Development Committee, Public…
Updates
-
The MyCheckpoint℠ clinical trial, conducted in collaboration with 18 of the Multiple Myeloma Research Consortium® (MMRC®) sites was designed to test the safety and feasibility of novel immune checkpoints in relapsed #myeloma patients. Results from this trial show that next-gen immune checkpoint inhibitors with the IMiD Pomalyst (pomalidomide) are safe and effective in relapsed multiple myeloma patients. This in turn paves the way for innovative, rational combinations of checkpoint inhibitors with CAR-T and bispecific antibodies, to unleash the full potential of immune therapy to treat and ultimately cure myeloma. “This is truly a team effort, made possible by the Multiple Myeloma Research Foundation and the MMRC,” commented Madhav V. Dhodapkar, MD, co-author on the publication and Brock Chair and Professor of Hemtaology/Medical Oncology at Emory University. “The finding that both TIGIT and LAG3 blockade have clinical activity in myeloma sets the stage for further investigations, including in patients who have received CAR Ts or bispecifics.” Read the full publication here: https://ow.ly/TVCU50T6ume
-
No matter what your #myeloma journey looks like, our MMRF Patient Navigation Center is here to: 💬 Guide you to information & resources 💜 Offer emotional support 🏥 Give a perspective on treatment options To learn more and connect with a Patient Navigator, visit: https://ow.ly/5Nt750SY1Mk
-
-
In ONE week, September marks the beginning of #BloodCancerAwarenessMonth! It’s a month dedicated to raising awareness and sharing signs and symptoms to help improve diagnosis and ultimately find a cure. Comment below what this upcoming month means to you.
-
-
In the words of CoMMpass PI and longtime MMRF partner Dr. Sagar Lonial, our CoMMpass℠ Study is more relevant today than it was 10 years ago when it first launched. CoMMpass, the largest single sequencing study of #multiplemyeloma to date, has made it possible to understand more about the biology of myeloma and how patients may progress and respond to therapy, which is important information that can chart the path to effective treatment. Together with our partners, like Dr. Lonial, we are using groundbreaking data sets like CoMMpass to fuel a new generation of #myeloma treatments and cures. Watch the film: https://lnkd.in/ezWfqusa
-
Healthcare professionals: On our #Myeloma Matters podcast, Drs. Saad Usmani and Joshua Richter discuss recent advances on bispecific antibodies for RRMM as discussed at the 2024 ASCO and EHA annual meetings—and what they mean for your practice. Watch the episode here: https://lnkd.in/e-8peKUH
Bispecific Antibody Horizons: Dosing Strategies and Meeting Updates in Myeloma Care
https://www.youtube.com/
-
Earlier this week, we shared a press release for the publication of an important new seminal paper on our CoMMpass℠ study in Nature Genetics. The paper, coauthored by investigators from the MMRF, Winship Cancer Institute of Emory University, and TGen - Part of City of Hope defines distinct subtypes and identifies new targets for #myeloma treatments. As MMRF President & CEO Michael Andreini shared of CoMMpass, “we recognized the critical need for comprehensive longitudinal data to truly understand the natural history of multiple myeloma, especially in a real-world setting where such data is scarce. And as an organization that has spent more than 25 years fiercely committed to changing the trajectory of multiple myeloma, we were the only ones positioned to build a truly collaborative initiative that could unite the multiple myeloma community and deliver the scale necessary to produce these types of scientific findings. We’re grateful to the clinical investigators at all the sites, and especially the patients who helped us accelerate this important research.” Read the full publication here: https://ow.ly/uO1Z50T2vtr
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes | Nature Genetics
nature.com
-
Today, we announced the publication of the seminal paper on our CoMMpass℠ study in Nature Genetics. Over ten years ago, we launched CoMMpass with more than 76 sites in 4 countries. It is now the largest longitudinal genomic data set in #myeloma and has transformed how researchers understand the biology of the disease, deepening our knowledge of high-risk disease and identifying new targets for drug discovery. Together with our partners, notably Winship Cancer Institute of Emory University and TGen - Part of City of Hope, CoMMpass data has led to unprecedented insights that have informed and will continue to inform efforts to optimize treatments for every patient. Read the full press release here: https://ow.ly/Z9k550T1gm2
Multiple Myeloma Research Foundation (MMRF) Announces New Publication on CoMMpass℠ Study in Nature Genetics Defining Distinct Subtypes of Multiple Myeloma and High-Risk Genetic Markers
globenewswire.com
-
Our MMRF Fast Facts in #Myeloma series is a collection of patient-friendly one-page guides designed to explain different aspects of having and managing #multiplemyeloma. To learn more about your disease, download one today: https://ow.ly/L8Uw50SY0Ru
-
-
Our vision is a world free of #myeloma. Will you stand with us and help to accelerate a cure for the nearly 180,000 people in the US who are living with #multiplemyeloma today? Your support has the power to change lives - donate to the MMRF: https://ow.ly/Prpk50SXZP8 #NationalNonprofitDay
-